Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 307

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects

Open access
Trojanowski, John Q., Vandeerstichele, Hugo, Korecka, Magdalena, Clark, Christopher M., Aisen, Paul S., Petersen, Ronald C., Blennow, Kaj, Soares, Holly, Simon, Adam, Lewczuk, Piotr, Dean, Robert, Siemers, Eric, Potter, William Z., Weiner, Michael W., Jack, Clifford R., Jagust, William, Toga, Arthur W., Lee, Virginia M.‐Y., Shaw, Leslie M., Alzheimer's Disease Neuroimaging Initiative·2010·Alzheimer's & Dementia
DOI 10.1016/j.jalz.2010.03.008
Open this paper in CoChat — free account

Abstract

Here, we review progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimer's disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. The Penn Biomarker Core also collaborated with other ADNI Cores to integrate data across ADNI to temporally order changes in clinical measures, imaging data, and chemical biomarkers that serve as mileposts and predictors of the conversion of normal control to MCI as well as MCI to AD, and the progression of AD. Initial CSF studies by the ADNI Biomarker Core revealed a pathological CSF biomarker signature of AD defined by the combination of Aβ1‐42 and total tau (T‐tau) that effectively delineates mild AD in the large multisite prospective clinical investigation conducted in ADNI. This signature appears to predict conversion from MCI to AD. Data fusion efforts across ADNI Cores generated a model for the temporal ordering of AD biomarkers which suggests that Aβ amyloid biomarkers become abnormal first, followed by changes in neurodegenerative biomarkers (CSF tau, F‐18 fluorodeoxyglucose‐positron emission tomography, magnetic resonance imaging) with the onset of clinical symptoms. The timing of these changes varies in individual patients due to genetic and environmental factors that increase or decrease an individual's resilience in response to progressive accumulations of AD pathologies. Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2010.03.008

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 307

Metadata

Authors
Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W. Z., Weiner, M. W., Jack, C. R., Jagust, W., Toga, A. W., Lee, V. M. ‐., Shaw, L. M., & Initiative, A. D. N.
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2010-05
Volume
6
Issue
3
Pages
230-238
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
DOI
10.1016/j.jalz.2010.03.008
OpenAlex
W2048674585
Cited by
307
References
15
FWCI
25.72
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. https://app.cochat.ai/papers/10.1016/j.jalz.2010.03.008
The paper
Trojanowski, J. Q., Vandeerstichele, H., Korecka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W. Z., Weiner, M. W., Jack, C. R., Jagust, W., Toga, A. W., Lee, V. M. ‐., Shaw, L. M., & Initiative, A. D. N. (2010). Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimer's & Dementia. https://doi.org/10.1016/j.jalz.2010.03.008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.